Sms Pharmaceuticals Limited · NSE:SMSPHARMA
Sms Pharmaceuticals — Q4 FY25 Earnings Presentation
23 slides from Sms Pharmaceuticals's earnings presentation, May 31, 2025
Slide 1: Cover letter to BSE and NSE
Date: 31st May, 2025 To, The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001 Mumbai
Slide 2: Investor Presentation Q4 & FY25
Investor Presentation Q4 & FY25 May 2025
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q4 & FY25 business and financial highlights
Quarterly Performance Review Q4 & FY25 business and financial highlights • FY25 EBITDA margin up 132 bps YoY to 18% due to backward integration Profitability • Full year PAT up 39% YoY, driven by scale and cost optimisation • FY25 Revenue grows 10% YoY with strong Q4 recovery Revenue (43% QoQ) drive
Slide 5: Q4FY25 financial highlights
Quarterly Performance Review Q4FY25 financial highlights REVENUE (₹ CRORE) EBITDA (₹ CR) MARGIN (%) PAT (₹ CR) MARGIN (%) EPS (₹) 11% 11% 246 248 20% 20% 8% 2.43 8% 197 16% 16% 2.04 1.95 164 173 14% 5% 1.69 1.4 41 20 34 34 31 35 17 16 18 12 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY24 Q1FY25 Q2FY25 Q3F
Slide 6: FY25 financial highlights
Quarterly Performance Review FY25 financial highlights REVENUE (₹ CRORE) EBITDA (₹ CR) MARGIN (%) PAT (₹ CR) MARGIN (%) EPS (₹) 783 18% 69 16% 7% 8.16 9% 50 139 5.89 117 709 FY24 FY25 FY24 FY25 FY24 FY25 FY24 FY25 ₹783 crore ₹ 139 crore ₹ 69 crore ₹8.16 Revenue from operations EBITDA PAT EPS ▲ 10% ▲
Slide 7: Key operating metrics Q4FY25
Quarterly Performance Review Key operating metrics Q4FY25 REVENUE BY THERAPEUTIC AREA (%) REVENUE BY GEOGRAPHY -WISE (%) 5% Europe Asia (Ex. India) North America EOU/SEZ/DE India 8% 8% 6% 9% 3% 5% 1% 5% 5% 6% 4% 11% 4% 11% 12% 13% 13% 10% 5% 7% 6% 7% 6% 9% 14% 12% 16% 14% 17% 24% 12% 10% Others 27%
Slide 8: Key operating metrics FY25
Quarterly Performance Review Key operating metrics FY25 REVENUE BY THERAPEU TIC AREA (%) REVENUE BY GEOGRAPHY -WISE (%) Europe Asia (Ex. India) North America EOU/SEZ/DE India 7% 7% 2% 4% 6% 13% 12% 6% 9% 7% 12% 20% 24% 14% Others Anti-epileptic 19% Anti-erectile dysfunction 17% Anti-ulcer 24% Anti-m
Slide 9: Company Overview
pharmaceuticals Itd. Company Overview
Slide 10: SMS at a Glance: Building a sustainable global business
SMS at a Glance Building a sustainable global business From a single unit-product facility to becoming a diversified API player with a global presence, we have… ⚫ Global and domestic leadership in key APIs ⚫ An integrated business model with accredited facilities ⚫ Strong presence in regulatory mark
Slide 11: 35+ history of delivering value
SMS at a Glance 35+ history of delivering value 1989 1995 2000 2003 2007 Inception Scaling Up Building our USFDA audit IPO-listing SMS Pharma was Became the world’s portfolio • Successful first SMS Pharma got started with a single largest Acquired a facility to USFDA audit listed on NSE and unit-pro
Slide 12: State-of-the-art, accredited manufacturing facilities
Our Strengths State-of-the-art, accredited manufacturing facilities Hyderabad unit Vizag unit Hyderabad Vizag Manufacturing capacity: 120 KL for niche small-volume Manufacturing capacity: 3,000 KL for niche large- molecules volume molecules Regulatory approvals: USFDA,EUGMP, KFDA,CDSCO,PMDA Regulato
Slide 13: Healthy product mix of high-value and high-volume products
Our Strengths Healthy product mix of high-value and high-volume products Therapeutic areas Key products Category Anti-inflammatory Ibuprofen High-volume Anti Retro Viral (ARV) Anti-diabetic Tenofovir Sitagliptin, Empagliflozin, High-volume 63:37 High-value Dapagliflozin, Vildagliptin Anti-migraine S
Slide 14: Strong thrust on R&D
Our Strengths Strong thrust on R&D New product development Added 20 new products Consistent investment in R&D Allocation of 2.4% of sales to R&D in FY25 Strong partnerships JV with Spanish pharma giant Chemo Iberica S.A. Large technical team 63+ scientists Focus on commercialisation 21 DMFs filed an
Slide 15: Diversified to mitigate risk and optimise growth
Our Strengths Diversified to mitigate risk and optimise growth REVENUE BY LOCATION, REVENUE BY CUSTOMER REVENUE BY CUSTOMER FY25 TYPE SIZE 0% 12% 22% 28% 31% 40% 24% 6% 72% 38% 27% 88% contribution from regulated Long-standing relationships with Largest customer contributed markets in FY25 marquee c
Slide 16: Marquee customer base
Our Strengths Marquee customer base 15
Slide 17: Experienced BoD to deliver on strategy
Our Strengths Experienced BoD to deliver on strategy Sri. Ramesh Babu Potluri Sri. Vamsi Krishna Potluri Sri. Shravan Kudravallii Sri. Sarvepalli Srinivas Chairman & Managing Director Executive Director Independent Director Director Sri. Dr. Suresh Kumar Sri. Sunkara Venkata Smt. Shanti Sree Bolleni
Slide 18: Strategies for growth
Way forward Strategies for growth Achieve global scale in • Aim to achieve a production target of 1,000 MT per month ibuprofen Leveraging diversified • Strong presence in both key high-margin and high-volume products portfolio for growth Backward integration to • Vertical integration of select produ
Slide 19: Robust growth is expected in revenue and profitability
Outlook Robust growth is expected in revenue and profitability REVENUE (₹ CR) Key Drivers: 783 709 563 Diversified product portfolio to drive revenue 520 522 Cost optimisation and enhanced operational efficiency enabled by scale FY21 FY22 FY23 FY24 FY25 EBITDA (₹ CR) MARGIN (%) 23% Improved profitab
Slide 20: Consolidated P&L statement
Financial statements Consolidated P&L statement YoY QoQ YoY Particulars (₹ Cr) Q4FY25 Q4FY24 Growth Q3FY25 Growth FY25 FY24 Growth (%) (%) (%) Revenue from Operations 248.20 245.80 1% 173.35 43% 782.75 709.26 10% COGS 173.32 182.55 -5% 106.24 63% 523.41 497.71 5% Gross Profit 74.88 63.25 18% 67.11 1
Slide 21: Consolidated Balance Sheet
Financial statements Consolidated Balance Sheet Particulars (Rs. crores) FY25 FY24 FY23 Total Equity 640 536 461 Non-Current Liabilities 189 166 164 Long Term Borrowings 139 122 121 Current Liabilities 324 332 255 Short Term Borrowings 171 158 131 Trade Payables 114 151 107 Total Equity and Liabilit
Slide 22: Consolidated Cash Flow Statement
Financial statements Consolidated Cash Flow Statement Particulars (Rs. crores) FY25 FY24 FY23 Cash flow from operating activities Profit before tax 92.34 66.11 5.35 Cash generated from operations 101.54 65.52 27.05 Cash flow from operating activities 81.71 50.12 22.45 Cash flow from investing activi
Slide 23: Thank You
Mr. Thirumalesh Tumma Aditya Dutta SMS Pharmaceuticals ltd EQSPONENT Partners LLP complianceofficer@smspharma.com smspharma.ir@eqsponent.com Thank You